Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIKNYSE:ISRNASDAQ:NYXHNASDAQ:PDEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIKAnika Therapeutics$10.92+3.1%$12.47$10.47▼$29.12$151.88M0.6771,547 shs81,160 shsISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsNYXHNyxoah$7.83+1.6%$6.94$5.55▼$11.87$262.61M1.6575,312 shs77,426 shsPDEXPro-Dex$41.82+3.2%$48.14$16.84▼$70.26$132.20M0.1732,820 shs101,689 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIKAnika Therapeutics+3.12%-1.71%-2.85%-29.18%-58.00%ISRIsoray0.00%0.00%0.00%0.00%0.00%NYXHNyxoah+1.56%+1.03%+1.16%-30.89%-7.99%PDEXPro-Dex+3.16%+3.08%-9.56%-15.72%+122.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIKAnika Therapeutics3.7387 of 5 stars3.82.00.03.60.71.70.6ISRIsorayN/AN/AN/AN/AN/AN/AN/AN/ANYXHNyxoah2.8592 of 5 stars3.53.00.00.02.70.00.6PDEXPro-Dex3.2579 of 5 stars3.52.00.00.02.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIKAnika Therapeutics 3.50Strong Buy$20.0083.15% UpsideISRIsoray 0.00N/AN/AN/ANYXHNyxoah 3.00Buy$14.5085.19% UpsidePDEXPro-Dex 3.00Buy$56.0033.91% UpsideCurrent Analyst Ratings BreakdownLatest ISR, PDEX, NYXH, and ANIK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/12/2025ANIKAnika TherapeuticsBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.004/21/2025NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/17/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/16/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2025NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIKAnika Therapeutics$119.91M1.31$0.10 per share111.02$10.51 per share1.04ISRIsoray$10.80M0.00N/AN/A$0.43 per share0.00NYXHNyxoah$4.89M54.54N/AN/A$3.60 per share2.18PDEXPro-Dex$53.84M2.53$0.99 per share42.34$9.03 per share4.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIKAnika Therapeutics-$56.38M-$3.88N/AN/AN/A-41.28%-7.22%-5.64%8/6/2025 (Estimated)ISRIsoray-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/ANYXHNyxoah-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)PDEXPro-Dex$2.13M$2.8014.9420.30N/A14.61%29.08%16.19%9/4/2025 (Estimated)Latest ISR, PDEX, NYXH, and ANIK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIKAnika TherapeuticsN/AN/AN/AN/AN/AISRIsorayN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIKAnika TherapeuticsN/A5.734.53ISRIsorayN/A14.3813.99NYXHNyxoah0.223.593.35PDEXPro-Dex0.282.731.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIKAnika Therapeutics91.53%ISRIsoray11.32%NYXHNyxoahN/APDEXPro-Dex15.28%Insider OwnershipCompanyInsider OwnershipANIKAnika Therapeutics9.64%ISRIsoray2.42%NYXHNyxoahN/APDEXPro-Dex47.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIKAnika Therapeutics30014.34 million12.96 millionOptionableISRIsorayN/A142.11 million138.67 millionNot OptionableNYXHNyxoah11034.06 millionN/ANot OptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionableISR, PDEX, NYXH, and ANIK HeadlinesRecent News About These CompaniesInvestors Shouldn't Overlook The Favourable Returns On Capital At Pro-Dex (NASDAQ:PDEX)June 23 at 7:38 AM | finance.yahoo.comHere is Why Growth Investors Should Buy ProDex (PDEX) NowJune 17, 2025 | zacks.comProDex (PDEX) Upgraded to Buy: Here's WhyJune 17, 2025 | zacks.comPro-Dex (NASDAQ:PDEX) Price Target Raised to $56.00 at Ascendiant Capital MarketsMay 28, 2025 | marketbeat.comAre Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?May 20, 2025 | finance.yahoo.comPro-Dex: Crash After Strong Earnings Leads To A Buying OpportunityMay 5, 2025 | seekingalpha.comHere's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of InvestorsMay 4, 2025 | uk.finance.yahoo.comPro-Dex, Inc. (PDEX) Q3 Earnings Surpass EstimatesMay 1, 2025 | zacks.comPro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month ResultsMay 1, 2025 | accessnewswire.comProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?April 25, 2025 | zacks.comTake the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in FocusApril 21, 2025 | zacks.comProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?April 3, 2025 | zacks.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 SharesApril 2, 2025 | insidertrades.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 SharesApril 1, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,096 Shares of StockMarch 28, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 5,151 Shares of StockMarch 18, 2025 | insidertrades.comWith 38% ownership in Pro-Dex, Inc. (NASDAQ:PDEX), hedge funds investors have a lot riding on the businessMarch 11, 2025 | finance.yahoo.comProDex (PDEX) Upgraded to Strong Buy: Here's What You Should KnowFebruary 28, 2025 | zacks.com(PDEX) Investment ReportFebruary 8, 2025 | news.stocktradersdaily.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 1,100 Shares of StockFebruary 4, 2025 | insidertrades.comPro-Dex, Inc. Reports Strong Q2 Growth in 2025January 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBetting on Disruption: Is Lemonade the Future of Insurance?By Jeffrey Neal Johnson | June 12, 2025View Betting on Disruption: Is Lemonade the Future of Insurance?ISR, PDEX, NYXH, and ANIK Company DescriptionsAnika Therapeutics NASDAQ:ANIK$10.92 +0.33 (+3.12%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$10.92 -0.01 (-0.05%) As of 06/23/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Isoray NYSE:ISRIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.Nyxoah NASDAQ:NYXH$7.83 +0.12 (+1.56%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$7.80 -0.03 (-0.38%) As of 06/23/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Pro-Dex NASDAQ:PDEX$41.82 +1.28 (+3.16%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$41.73 -0.09 (-0.22%) As of 06/23/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
